This series of commentaries, from representatives of worldwide clinical trial groups, gives an update on each group's most interesting and important current trials in breast cancer. For more information on this series' aims, read the Editorial by Section Editors Martine Piccart and Eric Winer.

For comment on the latest developments in other areas of breast cancer research, see our Commentaries page.